Matrix Metalloproteinase-9 as a Novel Player in Synaptic Plasticity and Schizophrenia: Table 1.

Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways

(2015)   NATURE NEUROSCIENCE

Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials

(2014) Kazuto Oya et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Genetic Removal of Matrix Metalloproteinase 9 Rescues the Symptoms of Fragile X Syndrome in a Mouse Model

(2014) H. Sidhu et al.   JOURNAL OF NEUROSCIENCE

De novo mutations in schizophrenia implicate synaptic networks

(2014) Menachem Fromer et al.   NATURE

Synaptic plasticity mediating cocaine relapse requires matrix metalloproteinases

(2014) Alexander C W Smith et al.   NATURE NEUROSCIENCE

Neuroligins, synapse balance and neuropsychiatric disorders

(2014) Marzena Maćkowiak et al.   Pharmacological Reports

Synaptically Released Matrix Metalloproteinase Activity in Control of Structural Plasticity and the Cell Surface Distribution of GluA1-AMPA Receptors

(2014) Zsuzsanna Szepesi et al.   PLoS One

Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial

(2014) Fang Liu et al.   SCHIZOPHRENIA RESEARCH

Role for MMP-9 in stress-induced downregulation of nectin-3 in hippocampal CA1 and associated behavioural alterations

(2014) Michael A. van der Kooij et al.   Nature Communications

Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes

(2014) Christos G. Gkogkas et al.   Cell Reports

High MMP-9 activity levels in fragile X syndrome are lowered by minocycline

(2013) Magdalena Dziembowska et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Genetically encoded FRET-based biosensor for imaging MMP-9 activity

(2013) Michal Stawarski et al.   BIOMATERIALS

Maintenance of long-term potentiation in hippocampal mossy fiber-CA3 pathway requires fine-tuned MMP-9 proteolytic activity

(2013) Grzegorz Wiera et al.   HIPPOCAMPUS

Gene expression profiling in treatment-naive schizophrenia patients identifies abnormalities in biological pathways involving AKT1 that are corrected by antipsychotic medication

(2013) Nishantha Kumarasinghe et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Subcellular localization of intercellular adhesion molecule-5 (telencephalin) in the visual cortex is not developmentally regulated in the absence of matrix metalloproteinase-9

(2013) Emily A. Kelly et al.   JOURNAL OF COMPARATIVE NEUROLOGY

Early postnatal expression and localization of matrix metalloproteinases-2 and -9 during establishment of rat hippocampal synaptic circuitry

(2013) Paven K. Aujla et al.   JOURNAL OF COMPARATIVE NEUROLOGY

A Randomized Double-Blind, Placebo-Controlled Trial of Minocycline in Children and Adolescents with Fragile X Syndrome

(2013) Mary Jacena S. Leigh et al.   JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS

The Fragile X Mental Retardation Protein Regulates Matrix Metalloproteinase 9 mRNA at Synapses

(2013) A. Janusz et al.   JOURNAL OF NEUROSCIENCE

Reward Learning Requires Activity of Matrix Metalloproteinase-9 in the Central Amygdala

(2013) E. Knapska et al.   JOURNAL OF NEUROSCIENCE

Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine

(2013) Hidenaga Yamamori et al.   NEUROSCIENCE LETTERS

A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia

(2013) Tomihisa Niitsu et al.   PSYCHIATRY RESEARCH

Activity-Dependent Local Translation of Matrix Metalloproteinase-9

(2012) M. Dziembowska et al.   JOURNAL OF NEUROSCIENCE

Neural mechanisms of social risk for psychiatric disorders

(2012) Andreas Meyer-Lindenberg et al.   NATURE NEUROSCIENCE

Synaptic circuit remodelling by matrix metalloproteinases in health and disease

(2012) George W. Huntley   NATURE REVIEWS NEUROSCIENCE

Transsynaptic Signaling by Activity-Dependent Cleavage of Neuroligin-1

(2012) Rui T. Peixoto et al.   NEURON

Role of pro-brain-derived neurotrophic factor (proBDNF) to mature BDNF conversion in activity-dependent competition at developing neuromuscular synapses

(2012) H. S. Je et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology

(2011) P. Michaluk et al.   JOURNAL OF CELL SCIENCE

Enhanced neuronal plasticity and elevated endogenous sAPPα levels in mice over-expressing MMP9

(2011) Apostolia Fragkouli et al.   JOURNAL OF NEUROCHEMISTRY

The role of BDNF in the pathophysiology and treatment of schizophrenia

(2011) Gabriela Favalli et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Better understanding of mechanisms of schizophrenia and bipolar disorder: From human gene expression profiles to mouse models

(2011) Chi-Ying Lin et al.   NEUROBIOLOGY OF DISEASE

The C(−1562)T polymorphism of matrix metalloproteinase-9 gene is associated with schizophrenia in China

(2011) Hongying Han et al.   PSYCHIATRY RESEARCH

Open-label add-on treatment trial of minocycline in fragile X syndrome

(2010) Carlo Paribello et al.   BMC Neurology

Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene in alcohol dependence: Family and case control study

(2010) Agnieszka Samochowiec et al.   BRAIN RESEARCH

Metzincin Proteases and Their Inhibitors: Foes or Friends in Nervous System Physiology?

(2010) S. Rivera et al.   JOURNAL OF NEUROSCIENCE

Fragile X: Leading the way for targeted treatments in autism

(2010) Lulu W. Wang et al.   Neurotherapeutics

Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control Collections

(2010) Enrico Domenici et al.   PLoS One

Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia

(2010) Sheng-Huang Chang et al.   PSYCHIATRY RESEARCH

Quantitative analyses of matrix metalloproteinase activity after traumatic brain injury in adult rats

(2009) Takuro Hayashi et al.   BRAIN RESEARCH

A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia

(2009) Yechiel Levkovitz et al.   JOURNAL OF CLINICAL PSYCHIATRY

Matrix Metalloproteinase-9 Controls NMDA Receptor Surface Diffusion through Integrin  1 Signaling

(2009) P. Michaluk et al.   JOURNAL OF NEUROSCIENCE

Matrix Metalloproteinase-9 Gene and Bipolar Mood Disorder

(2009) Janusz K. Rybakowski et al.   NEUROMOLECULAR MEDICINE

Functional polymorphism of the matrix metalloproteinase-9 (MMP-9) gene in schizophrenia

(2009) Janusz K. Rybakowski et al.   SCHIZOPHRENIA RESEARCH

Important role of matrix metalloproteinase 9 in epileptogenesis

(2008) Grzegorz M. Wilczynski et al.   JOURNAL OF CELL BIOLOGY

High resolution in situ zymography reveals matrix metalloproteinase activity at glutamatergic synapses

(2008) M. Gawlak et al.   NEUROSCIENCE

Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately

(2008) X.-b. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline

(2007) Yuko Fujita et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY